There was no difference in OS between patients with WT KRAS tumours who did not receive anti-EGFR therapy and those who did (28.0 versus 26.9 months; HR: 1.13, 95% CI: 0.77–1.67; p = 0.5373) (Figure 3). Here, EGFR is linked to neoplasm.